SiBone (SIBN) News Today

SI-BONE, Inc. (NASDAQ: SIBN) reported a mixed but generally constructive third quarter, with results that help explain investor interest while insider selling may be weighing on the shares.

• Positive Sentiment: Quarterly results beat expectations. SI-BONE reported a third-quarter loss of $0.08 per share, better than the $0.13 loss analysts expected. Revenue rose 14.5% year over year to $55.7 million, narrowly exceeding the $55.31 million consensus estimate. Si-Bone Reports Q3 Loss, Tops Revenue Estimates
• Positive Sentiment: Profitability and cash flow improved. Adjusted EBITDA increased 32.4% to $3.0 million, while operating cash flow reached $5.9 million, up 154.4% from the prior-year period. SI-BONE ended the quarter with $146.3 million in cash and equivalents, supporting continued investment in growth. SI-BONE Reports Third-Quarter 2026 Results
• Positive Sentiment: Procedure growth and product catalysts remain favorable. U.S. procedure volume grew approximately 20%, the active U.S. physician base expanded 16% to 1,770, and the company reaffirmed its 2026 revenue guidance. FDA clearance for the iFuse Granite Onyx breakthrough device and new reimbursement rules that could increase hospital payments by up to $50,000 per qualifying procedure may support future adoption. SI-BONE Reports Third-Quarter 2026 Results
• Neutral Sentiment: The company remains unprofitable. SI-BONE posted a $3.6 million net loss, despite improving 20.7% year over year. Its negative net margin and return on equity indicate that the business has not yet reached sustained GAAP profitability.
• Negative Sentiment: Two insiders sold shares. SVP Michael Pisetsky sold 29,665 shares for approximately $655,893, reducing his holdings by 15.28%. Insider Anshul Maheshwari sold 3,738 shares for about $84,105. Although both executives retained substantial positions, the sales could create modest sentiment pressure, particularly with the stock trading near its 52-week high. Insider Sale Filing